Aptadir Therapeutics

Our CEO Giovanni Amabile has been interviewed by Mariavittoria Zaglio of CNBC Class for #SanitàNext about Aptadir Therapeutics and its RNA therapeutics platform Aptadir has been founded by Extend | the National Technology Transfer Biotech Hub an initiative of CDP Venture Capital SGR Angelini Ventures and Evotec Find more here at minute 28.30 https://lnkd.in/diDFAdx9

Today the national newspaper La Repubblica devotes an article to Aptadir Therapeutics regarding its innovative RNA technology and its potential to open novel therapeutic perspectives for intractable conditons find more below Giovanni Amabile Extend | the National Technology Transfer Biotech Hub CDP Venture Capital SGR Angelini Ventures Evotec #biotech #innovation #raredisease #madeinitaly #cancertreatment #RNAtherapy

Our CEO Giovanni Amabile had a chat with Uduak Grace Thomas editor of Genetic Engineering & Biotechnology News about Aptadir Therapeutics and its disruptive RNA technology resulting in an outstanding article published in #GEN #biotech #RNAtherapeutics #geneticdiseases #cancertreatment #innovation #innovativemedicines #XFragileSyndrome #epigenetics Extend | the National Technology Transfer Biotech Hub find out more here: https://lnkd.in/eNnnQjxz

Aptadir Therapeutics launched with preclinical targeted therapies for cancer and genetic disorders this week! ?? ? The Italian startup’s $1.6 million launch will fuel the development of a new class of investigational drugs. Aptadir’s technology is one of a kind. It is designed to address DNA hypermethylation, an aberration that can result in cancer and various genetic disorders. ?? ?? At present, Aptadir is focused on treating myelodysplastic syndrome, a type of blood cancer, and the genetic disorder fragile X syndrome. Read our latest article to find out more about this novel technology and Aptadir’s pipeline! ?? https://lnkd.in/dKKRaxh6 #cancerresearch #geneticdisorders #preclinicalresearch #innovativetherapies #biotechinnovation #therapeuticdevelopment #biotechnews #biopharma Giovanni Amabile | Assobiotec

our CEO Giovanni Amabile was interviewed by the italian newspaper Sole24 ore which published an article about Aptadir Therapeutics and its potential in developing disease-modifying treatments for underserved conditions #biotech #madeinitaly #startups #cancertreatment #raredisease #RNAtherapeutics #innovation #teamwork Giovanni Amabile Annalisa D. Vittorio de Franciscis Daniel Tenen Marcin Kortylewski

We are proud to announce the launch of?Aptadir Therapeutics and the appointment of our Executive Chairman and acting CEO,?Giovanni Amabile. Aptadir has a novel approach for intractable cancers and genetic conditions in both adults and children. Our platform is based on a landmark discovery of a new class of RNA inhibitors called DNMTs Interacting RNAs (DiRs)?which can block aberrant DNA methylation at a single gene level, reactivating previously hypermethylated genes – a key feature in cancer and genetic disorders such as MDS and Fragile X Syndrome. The origin of our science is from 3 top international institutions The Beth Israel Deaconess Medical Center of the?Harvard Medical School The?Italian National Research Council (CNR) The?Cancer Science Institute of Singapore And thank you to the support from?CDP Venture Capital SGR,?Angelini Ventures and?Evotec SE, making us the?very first?investment of the Extend | the National Technology Transfer Biotech Hub joint venture. Follow us at?Aptadir Therapeutics or visit our website at?https://aptadir.com?for more news about the company and our developing pipeline. #MyelodysplasticNeoplasms, #FragileX, #biopharma, #biotech #startups #rarediseases #companybuilding Giovanni Amabile Claudia Pingue Davide Santi Simone Braggio Antonio Felici Carlo Bertozzi Paolo Di Giorgio Lola Buono Annalisa D. Vittorio de Franciscis Daniel Tenen Marcin Kortylewski